New research shows an AI-powered chatbot trained to deliver cognitive behavioral therapy significantly reduced anxiety, ...

The study, published in The Lancet, a team from the Moorfields Eye Hospital and University College London Institute of ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Oncolytic virus therapy is emerging as a low-cost, targeted cancer treatment. With over 60 trials in China, scientists see ...

Ideaya Biosciences (IDYA) announced that the FDA has granted breakthrough therapy designation for darovasertib, a protein kinase C inhibitor, ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...

Vision is one of the most crucial human senses, yet over 300 million people worldwide are at risk of vision loss due to ...

A phase 3 trial plans to further assess neoadjuvant darovasertib for the potential treatment of patients with primary uveal melanoma.

NMPA Breakthrough Therapy Designation is intended to facilitate and expedite the development and review of investigational drugs for serious diseases or conditions when preliminary clinical ...

Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...